7th March 2022
PRESS RELEASE
As a new step in its development, BioMAdvanced Diagnostics is thrilled to announce the start of its Quality Affairs & Regulatory Affairs Manager, Madeleine Rambeau, who started this morning and was welcome by the Company Founders. A new step towards bringing our groundbreaking solutions to the clinicians and their patients.
As a reminder, BioMAdvanced Diagnostics, a BioTech/MedTech start-up from Nantes, a spinoff from the CR2TI laboratory (Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, INSERM – University of Nantes) and from the University Hospital (CHU) of Nantes, which aims to offer companion molecular diagnostic tests and biomarkers in connection with the immune response of patients. On the basis of a common technological base, the first applications will concern: 1) improving the follow-up of patients who have received a kidney or lung transplant, and 2) determining the best drug to administer to patients with ulcerative colitis (UC). These tests are designed to be integrated into standard diagnostic and treatment protocols, easy to use by staff caring for targeted patients. Predictive scores are produced using algorithms based on the combination of signatures from the expression of selected genes and clinical parameters.